Compare Mesoblast Limited (MESO) vs Tencent Music Entertainment Group - ADR (TME) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Tencent Music Entertainment Group - ADR — how do they compare? Mesoblast Limited trades at $14.3 (market cap $1.75B), while Tencent Music Entertainment Group - ADR trades at $8.34 (market cap $12.83B). The key difference: Tencent Music Entertainment Group - ADR is far larger — about 7.3× Mesoblast Limited's market cap, and Tencent Music Entertainment Group - ADR pays a 3.02% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 15 Days and Tencent Music Entertainment Group - ADR for 67 Days on average.
| MESO | TME | |
|---|---|---|
Market Cap | $1.75B | $12.83B |
Volume | 239,027 | 3,618,478 |
Sector | Health | Media |
52-Week High | $20.96 | $23.71 |
52-Week Low | $13.19 | $7.74 |
Typical Hold Time | 15 Days | 67 Days |
Enterprise Value | $1.83B | $10.77B |
Dividend Yield | — | 3.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
TME trades at $8.38, up 4.88% today, but technical indicators are bearish overall. The company reported strong 2025 results with revenue of $32.9B and net income of $11.06B, though recent quarters show mixed earnings performance. Analyst sentiment is mixed with a consensus price target of $12.50, and the stock appears undervalued with a P/E of 9.33 and P/S of 2.46.
The outlook is balanced: attractive valuation and profitability support upside potential, but bearish technicals, competitive pressures, and recent net cash outflows pose risks. Investors should weigh strong fundamentals against near-term headwinds and market sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Tencent Music Entertainment Group - ADR
TME is the largest online music service provider in China. It was founded in 2016 with the business combination of QQ Music (founded in 2005), Kuwo Music (founded in 2005) and Kugou Music (founded in 2004) streaming platforms. Tencent is the largest shareholder of TME with over 50% shares and over 90% voting rights held. TME also provides social entertainment services, including music live audio/video broadcasts and online concert services through the three platforms mentioned above, and online karaoke through an independent platform WeSing.
Read more on TME →
